Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

IPO Prophet® is a real-time IPO intelligence platform that gives investors a data-driven edge. Our team brings over 75 years of combined experience trading and investing in IPOs, translating firsthand market execution into proprietary quantitative analytics designed for today’s issuance environment.

Unlike traditional research providers that rely solely on commentary and retrospective analysis, IPO Prophet® is grounded in actual trading experience across multiple IPO cycles. Our platform integrates live market data, historical performance benchmarks, and predictive models to help investors evaluate deal quality, pricing discipline, demand strength, and post-IPO trading behavior as it unfolds.

From pre-deal analysis through pricing and aftermarket performance, IPO Prophet® delivers actionable, data-driven intelligence that helps investors make informed decisions at the moments that matter most.

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

Latigo Biotherapeutics / Equity Capital Markets

<ul><li>The IPO market showed signs of its traditional late-summer slowdown Friday as Latigo Biotherapeutics (LTGO) and BlossomHill Therapeutics (BLSM) made their Nasdaq debuts. Both biotechnology offerings found enough support to avoid significant breaks below their IPO prices by the close, but neither produced the sustained aftermarket momentum that characterized some of the stronger new issues earlier this summer.</li><li>Latigo priced 19.2 million shares at $18.00, raising approximately $346 million, and opened at $21.00, a 16.7% premium to its IPO price.</li><li>The shares initially traded as high as $22.47, but the early strength quickly faded. LTGO ultimately closed at $18.25, down 13.1% from its opening trade and just 1.4% above its IPO price, on approximately 2.59 million shares of volume.</li></ul>

The IPO market showed signs of its traditional late-summer slowdown Friday as Latigo Biotherapeutics (LTGO) and BlossomHill Therapeutics (BLSM) made their Nasdaq debuts. Both biotechnology offerings found enough support to avoid significant breaks below their IPO prices by the close, but neither produced the sustained aftermarket momentum that characterized some of the stronger new issues earlier this summer.Latigo priced 19.2 million shares at $18.00, raising approximately $346 million, and opened at $21.00, a 16.7% premium to its IPO price.The shares initially traded as high as $22.47, but the early strength quickly faded. LTGO ultimately closed at $18.25, down 13.1% from its opening trade and just 1.4% above its IPO price, on approximately 2.59 million shares of volume.

Summer Doldrums Set In as Latigo (LTGO) And BlossomHill (BLSM) Close Out a Quieter Week